Roger Gunn is Professor of Molecular Neuroimaging in the Division of Brain Sciences at Imperial College London. Professor Gunn has a background in applied mathematics and his research focuses on the application of positron emission tomography (PET) and magnetic resonance imaging (MRI) technologies to the study of pathophysiology and drug development in humans. A particular focus is the development of molecular PET probes to image targets in the brain - this includes the discovery and validation of the novel probes themselves, the associated development of quantitative analysis methods and the application of these tools in clinical studies exploring disease processes and their treatment.
Professor Gunn received his undergraduate training in applied mathematics and a PhD in bio-mathematical modelling of Positron Emission Tomography (PET) data from the University of Warwick. He has worked previously at the MRC Cyclotron Unit (London, UK), held a faculty position at McGill University where he worked at the Montreal Neurological Institute before joining GSK in 2003 to help establish their Clinical Imaging Centre.In October 2011 he took up the position of Chief Scientific Officer and Head of Analysis at Imanova which is a joint venture between Imperial, UCL, Kings and the MRC targeted at providing high quality R&D imaging capabilities to the London Universities and Commercial organisations. He also holds a Visiting Professorship at Oxford University (Department of Engineering Science) and has published 120 peer reviewed journal articles in the field of imaging. Professor Gunn has served as a panel member for the MRC and on organising and programme committees at numerous conferences - he was recently Co-Chair of BrainPET 2011.
et al., 2022, Neurons derived from individual early Alzheimer's disease patients reflect their clinical vulnerability, Brain Communications, Vol:4
et al., 2022, Brain Serotonin Release Is Reduced in Patients With Depression: A [11C]Cimbi-36 Positron Emission Tomography Study With a d-Amphetamine Challenge., Biol Psychiatry
et al., 2022, Evaluation of Intraperitoneal [F-18]-FDOPA Administration for Micro-PET Imaging in Mice and Assessment of the Effect of Subchronic Ketamine Dosing on Dopamine Synthesis Capacity, Molecular Imaging, Vol:2022
et al., 2022, Astrogliosis in aging and Parkinson’s disease dementia: a new clinical study with 11C-BU99008 PET, Brain Communications, Vol:4, ISSN:2632-1297
et al., 2022, Widespread cell stress and mitochondrial dysfunction occur in patients with early Alzheimer’s Disease, Science Translational Medicine, Vol:14, ISSN:1946-6234, Pages:1-11